Purpose To evaluate the safety and efficacy of surgical implantation of prosthetic iris devices in patients with iris deficiency. Methods Nine patients with traumatic iris defects, congenital aniridia or iris coloboma, and surgical or optical iridectomies were included in a noncomparative case series. Cataract surgery with intraocular lens and prosthetic iris implantation was performed in 10 eyes. The visual acuity, subjective degree of glare disability, postoperative anatomic results, and intraoperative and postoperative complications were evaluated. Results The mean follow-up was 17.75 months (range 4-48 months). Best-corrected visual acuity improved in nine of 10 eyes (90%) and remained unchanged in one eye. Glare subjectively improved in four of five eyes (80%) of patients complaining of glare preoperatively. All eyes achieved the desired anatomic result. Intraoperative complications included one anterior capsular tear. Postoperative complications included a short period of mild postoperative anterior uveitis in four eyes. Secondary glaucoma was absent. Conclusion In patients with iris deficiency, implantation of prosthetic iris device, and intraocular lens implant following cataract surgery appears to be safe and effective in reducing glare disability and improving visual outcomes.
Purpose: Preserflo Microshunt surgery is a new surgical procedure in the management of glaucoma. We evaluated the effectiveness and safety of Preserflo Microshunt surgery throughout the first 6 months postoperatively, by comparing intraocular pressure (IOP), number of drop agents pre and post operatively and any registered complications. Methods: A case series of 30 patients with primary open angle glaucoma underwent Preserflo Microshunt surgery at a District General Hospital in the UK. Surgical technique included scleral application of Mitomycin C 0.4 mg/mL for 3 minutes prior to microshunt insertion. Patients had their intra ocular pressure recorded pre operatively, day 1, week 2, month 2 and after 6 months. The number of therapeutic agents in their glaucoma drops was also compared pre‐operatively and after 6 months. Results: Mean IOP was reduced form 17.4 mmHg at baseline to 8.9 mmHg at 2 months and 11.6 mmHg at 6 months. The mean number of drug agents reduced from 2.25 to 0.07, and a total of 28 out of 30 (93.3%) remained drop free at 6 months. There were three cases where patients required needling of the bleb, two subsequently required repositioning of the shunt, and an IOP spike at day one post operatively in one case. Conclusions: Early results for Preserflo Microshunt surgery show sustained reduction in IOP at 6 months, with the majority of patients requiring no glaucoma drops postoperatively. The surgery has been well tolerated by patients with less intense follow up compared to a traditional trabeculectomy and low complication rates.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.